+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Eisai Inc - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 35 Pages
  • October 2023
  • GlobalData
  • Eisai Co
  • ID: 1495870
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Eisai Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - A summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Eisai Inc (Eisai America), a subsidiary of Eisai Co Ltd, is a healthcare company that discovers, develops, and markets pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Banzel for adjunctive treatment, and Dayvigo for the insomnia. The company’s research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory, and immunological reaction. Eisai America established partnerships and collaborations with global companies such as Pfizer, Janssen Pharmaceutica Inc, Elan Pharma International Ltd, and Elan Pharmaceutical Inc for the development and distribution of drugs. Eisai America is headquartered in New Jersey, the US.

Eisai Inc Key Recent Developments

  • Apr 11,2023: Eisai and patient advocacy partners launch Made of More - An education initiative to spotlight head and neck cancer
  • Aug 18,2022: Eisai reinforces commitment to collaboration and innovation to support patients and communities through new U.S. headquarters
  • Jun 02,2022: Eisai to Present Latest Data on Lemborexant at the 36th Annual Sleep 2022 Meeting
  • Mar 15,2022: Biogen and Eisai revise agreements on Alzheimer’s disease therapies

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with a detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Eisai Inc - Key Facts
  • Eisai Inc - Key Employees
  • Eisai Inc - Key Employee Biographies
  • Eisai Inc - Major Products and Services
  • Eisai Inc - History
  • Eisai Inc - Company Statement
  • Eisai Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Eisai Inc - Business Description
  • Eisai Inc - Corporate Strategy
  • Eisai Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Eisai Inc - Strengths
  • Eisai Inc - Weaknesses
  • Eisai Inc - Opportunities
  • Eisai Inc - Threats
  • Eisai Inc - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Eisai Inc, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Apr 11, 2023: Eisai and patient advocacy partners launch Made of More - An education initiative to spotlight head and neck cancer
  • Aug 18, 2022: Eisai reinforces commitment to collaboration and innovation to support patients and communities through new U.S. headquarters
  • Jun 02, 2022: Eisai to Present Latest Data on Lemborexant at the 36th Annual Sleep 2022 Meeting
  • Mar 15, 2022: Biogen and Eisai revise agreements on Alzheimer’s disease therapies
  • Jan 24, 2022: Eisai announces the appointment of tricia brooks as vice president & head of office, government affairs and policy
  • Jan 19, 2022: Eisai listed as a Global 100 most sustainable corporation for the sixth time
  • Jan 13, 2022: Eisai’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
Section 5 - Appendix
  • Methodology
  • Contact Us
  • Disclaimer
List of Tables
  • Eisai Inc, Key Facts
  • Eisai Inc, Key Employees
  • Eisai Inc, Key Employee Biographies
  • Eisai Inc, Major Products and Services
  • Eisai Inc, History
  • Eisai Inc, Other Locations
  • Eisai Inc, Subsidiaries
  • Eisai Inc, Key Competitors
  • Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Eisai Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Eisai Inc, Recent Deals Summary
List of Figures
  • Eisai Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Eisai Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • White River Health System
  • Research Foundation for Mental Hygiene Inc
  • Wellstat Therapeutics Corp
  • Salix Pharmaceuticals Ltd
  • Koronis Pharmaceuticals, Inc.
  • CerFlux Inc
  • Ceregene Inc
  • Adlyfe Inc